↓ Skip to main content

Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.

Overview of attention for article published in Current Pharmaceutical Design, January 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
76 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
Published in
Current Pharmaceutical Design, January 2018
DOI 10.2174/1381612823666171109112307
Pubmed ID
Authors

Sayed Sartaj Sohrab, Sherif Aly El-Kafrawy, Zeenat Mirza, Mohammad Amjad Kamal, Esam Ibraheem Azhar

Abstract

The MERS-CoV is a novel human coronavirus causing respiratory syndrome since April 2012. The replication of MERS-CoV is mediated by ORF 1ab and viral gene activity can be modulated by RNAi approach. The inhibition of virus replication has been documented in cell culture against multiple viruses by RNAi approach. Currently, very few siRNA against MERS-CoV have been computationally designed and published. In this review, we have discussed the computationally designing and delivery of potential siRNAs. Potential siRNA can be designed to silence a desired gene by considering many factors like target site, specificity, length and nucleotide content of siRNA, removal of potential off-target sites, toxicity and immunogenic responses. The efficient delivery of siRNAs into targeted cells faces many challenges like enzymatic degradation and quick clearance through renal system. The siRNA can be delivered using transfection, electroporation and viral gene transfer. Currently, siRNAs delivery has been improved by using advanced nanotechnology like lipid nanoparticles, inorganic nanoparticles and polymeric nanoparticles. The efficacy of siRNA-based therapeutics has been used not only against many viral diseases but also against non-viral diseases, cancer, dominant genetic disorders, and autoimmune disease. This innovative technology has attracted researchers, academia and pharmaceuticals industries towards designing and development of highly effective and targeted disease therapy. By using this technology, an effective and potential siRNAs can be designed, delivered and their efficacy with toxic effects and immunogenic responses can be tested against MERS-CoV.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 76 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 18%
Student > Master 9 12%
Student > Bachelor 9 12%
Professor > Associate Professor 7 9%
Professor 5 7%
Other 13 17%
Unknown 19 25%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 15 20%
Medicine and Dentistry 9 12%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Nursing and Health Professions 3 4%
Agricultural and Biological Sciences 2 3%
Other 14 18%
Unknown 29 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2021.
All research outputs
#7,963,683
of 25,382,440 outputs
Outputs from Current Pharmaceutical Design
#1,254
of 3,701 outputs
Outputs of similar age
#148,319
of 449,550 outputs
Outputs of similar age from Current Pharmaceutical Design
#59
of 235 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,701 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,550 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 235 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.